Alzamend Neuro Files S-1/A Amendment
Ticker: ALZN · Form: S-1/A · Filed: Jun 26, 2024 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | S-1/A |
| Filed Date | Jun 26, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001, $0.39, $35 million, $2.5 million, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1/a, registration
TL;DR
Alzamend Neuro filed an S-1/A, looks like they're raising capital.
AI Summary
Alzamend Neuro, Inc. filed an amendment (S-1/A) on June 26, 2024, to its registration statement. The company, incorporated in Delaware, is in the pharmaceutical preparations sector and is headquartered in Atlanta, GA. This filing relates to the registration of securities under the Securities Act of 1933.
Why It Matters
This S-1/A filing indicates Alzamend Neuro is moving forward with a securities offering, which could impact its capital structure and future operations.
Risk Assessment
Risk Level: medium — S-1/A filings often precede significant corporate actions like stock offerings, which carry inherent market and execution risks.
Key Numbers
- 333-279920 — SEC File Number (Identifies the specific SEC registration filing.)
- 0430 — Fiscal Year End (Indicates the end of the company's fiscal year.)
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- Stephan Jackman (person) — Chief Executive Officer
- Henry Nisser (person) — Executive Vice President and General Counsel
- 333-279920 (dollar_amount) — SEC File Number
- 2834 (dollar_amount) — Standard Industrial Classification Code
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to a Form S-1 registration statement, typically filed to update information or provide details related to a securities offering.
When was this amendment filed?
The amendment was filed with the SEC on June 26, 2024.
What is Alzamend Neuro, Inc.'s primary business sector?
Alzamend Neuro, Inc. is classified under Pharmaceutical Preparations (SIC Code 2834).
Who is the CEO of Alzamend Neuro, Inc.?
Stephan Jackman is the Chief Executive Officer of Alzamend Neuro, Inc.
Where is Alzamend Neuro, Inc. headquartered?
The company's principal executive offices are located at 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.
Filing Stats: 4,566 words · 18 min read · ~15 pages · Grade level 16.6 · Accepted 2024-06-26 16:46:11
Key Financial Figures
- $0.0001 — 0,000 shares of common stock, par value $0.0001 per share (the "Common Stock"), of Alza
- $0.39 — orted by The Nasdaq Capital Market, was $0.39 per share. We are a "smaller reportin
- $35 million — LS") for our Common Stock was below the $35 million minimum MVLS requirement for continued
- $2.5 million — requires stockholder equity of at least $2.5 million (or an alternative listing standard), a
- $1.00 — e for the Common Stock had closed below $1.00 per share for the previous 30 consecuti
Filing Documents
- az625260s1a1.htm (S-1/A) — 318KB
- ex23_1.htm (EX-23.1) — 3KB
- alzamendlogo_med.jpg (GRAPHIC) — 24KB
- 0001214659-24-011445.txt ( ) — 355KB
RISK FACTORS
RISK FACTORS 5 PRIVATE PLACEMENT 8
DESCRIPTION OF SECURITIES BEING OFFERED
DESCRIPTION OF SECURITIES BEING OFFERED 12 SELLING STOCKHOLDER 13 PLAN OF DISTRIBUTION 14
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 15 LEGAL MATTERS 20 EXPERTS 20 INFORMATION INCORPORATED BY REFERENCE 20 WHERE YOU CAN FIND MORE INFORMATION 21 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC. The Selling Stockholder may, from time to time, sell up to 125,000,000 shares of our Common Stock, as described in this prospectus. We will not receive any proceeds from the sale by the Selling Stockholder of the securities described in this prospectus, provided, that we would receive certain proceeds in the event that the Selling Stockholder elects to exercise its Warrants. You should rely only on the information contained in this prospectus, any supplement to this prospectus or in any free writing prospectus, filed with the SEC. Neither we nor the Selling Stockholder have authorized anyone to provide you with additional information or information different from that contained in this prospectus, or any applicable prospectus supplement or any free writing prospectuses prepared by us or on our behalf and filed with the SEC. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Stockholder is offering to sell our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to the offering. The prospectus supplement or post-effective amendment, as the case may be, may add, update or change information contained in this prospectus with respect t